Pulp Dressing Agents Used in Primary Teeth: A Review of the Literature

Filareti-Efthymia Boulioni and Aristidis Arhakis

ABSTRACT

Background: Pulpotomy is a technique of vital pulp therapy which can be performed in a primary tooth with pulp exposure due to caries or trauma when there is no clinical or radiographic sign of irreversible pulpitis or necrosis. Since today many different medicaments and techniques have been researched as pulpotomy agents and studies have shown the effectiveness but also the limitations of them.

Aim: The aim of this literature review is to overview the medicaments which were used in the past for pulpotomy in primary teeth, but also to evaluate the techniques and medicaments from the present and the future.

Results: Formocresol was the first-choice material for many decades, but its use has been limited due to potential mutagenic and carcinogenic effects in humans. In addition, glutaraldehyde is no longer used as a material for pulpotomy due to its toxicity. Mineral trioxide aggregate (MTA) seems to have better or comparable success rates as the old gold standard – formocresol, while other materials have high effectiveness. Calcium hydroxide was related to lower success rate and due to adverse effects as the internal root resorption is no longer recommended. Electrosurgery and laser are alternative techniques, while collagen and enamel matrix derivative (EMD) have been researched the last years and also studies about the bone morphogenetic proteins (BMPs) presented promising results. Also, other medicaments, which have been evaluated as pulpotomy materials, are included in this review and they seem to lead to acceptable results.

Conclusions: MTA seems to be the new gold-standard for pulpotomy, while also other medicaments as ferric sulfate, sodium hypochlorite, Portland cement, Biodentine can lead to comparable results. Electrosurgery and laser pulpotomy are alternative and non-pharmacological techniques with good success rates, while also other alternative materials seem to have promising results, but further research is needed.

Keywords: Medicaments, primary teeth, pulpotomy.

I. INTRODUCTION

According to the Global Burden of Disease Study, tooth decay is the most common oral disease in permanent dentition, but it is also highly related to primary teeth with more than 530 million children worldwide suffering from dental caries [1]. Despite the progress in the field of the prevention of dental caries and the decrease of the prevalence and severity of dental caries lesions among 5- and 12-years old, a huge part of the world still suffers from this disease [2].

Untreated caries is one of the possible causes of pulp exposure which was traditionally treated with root canal therapy. However today, the management strategies of exposed pulp aim to the limitation of pulpectomy and the selection of the vital pulp techniques such as pulpotomy as the treatment of choice [3].

According to American Association of Pediatric Dentistry [4], pulpotomy is defined as the surgical removal of the coronal vital pulp tissue followed by placement of a biologically acceptable material in the pulp chamber and restoration of the tooth. Specific indications are considered to play a significant role for the success of this pulp therapy such as the presence of normal or reversible pulp tissue with pulp exposure due to caries or trauma with no radiographic signs of infection or pathologic resorption [2]. The aim of pulpotomy is to preserve the radicular pulp, avoiding pain and swelling and also to retain the tooth preserving the arch integrity while the remaining pulp tissue is vital without suppuration, purulence, necrosis, or uncontrolled hemorrhage [4], [5]. Key factors for the success of this pulp tissue treatment are among others the right diagnosis, the condition or/and the grade of the inflammation of the pulp, a final restoration which prevent the microleakage and the understanding of the physiological pulp response to the capping [3]. Furthermore, another key for the success of this treatment option is the selection of a suitable technique and medicament as pulp capping material. An ideal pulpotomy agent must have specific properties such as biocompatibility,
antibacterial activity, property to seal the remaining pulp tissue and not being resorbable. Also, it should promote the healing of the pulp, be harmless and not interfere the physiological root resorption [6]-[8]. Buckley's formocresol was first introduced as a pulpotomy medicament in 1904 and since 1930 was considered to be the gold standard material for this pulp tissue therapy [9], [10]. Although, over the years many techniques and materials have been developed as alternatives to formocresol and the main purpose of this literature review is to compare and evaluate these different procedures and medicaments based on the clinical, radiographical or/and histological results of the following studies.

II. PULP DRESSING MATERIALS

A. Formocresol

Formocresol was at first consisted of equal parts of formalin and tricresol intended to fix nonvital pulp tissue [11]. Over the years this composition changed, which led to the so-called «Buckley’s formula» with 19% formaldehyde, 35% cresol, glycerin, and water [12]. Formocresol has not the ability to promote dental bridge formation or odontogenesis, but its use aims to the devitalization of the dental pulp in teeth with deep caries [12]. It was characterized for many years as the “gold standard” medicament for pulpotomy in primary teeth with high clinical and radiographical success rates which were according to clinical studies between 73-98% [13]-[16]. Reference [13] showed that the clinical and radiographical success rate of formocresol was at 12-months follow-up 73.3% and they found some side effects of this medicament such as internal root resorption in the 6.3% of the treated primary teeth, external root resorption and furcation radiolucency in 20%. Reference [14] came to the result that pulpotomy with formocresol had 96% radiographic success rate after 12 months and, [15] showed 98.1% success rate after the same time period, with pulp canal obliteration as the most common radiographic observation due to the high odontoblastic activity as a proof of pulpal vitality. Also, according to the clinical study of [16], the radiographic success rate was significant different than the previous results (90%) and it was also important that the patients had no clinical signs of failure. Worth mentioning is also the histological evaluation after the use of formocresol as a capping material in a pulpotomy which showed that this material causes more times than others severe inflammation and sometimes necrosis maybe due to its property to devitalize the pulp tissue [17].

However, the last years serious concerns have been developed about the safety of formocresol as a used medicament in children due to formaldehyde. Formaldehyde has been associated with carcinogenesis, mutagenicity [18], [19], cytotoxicity and immune sensitization and it can cause 3 most common types of damages in DNA: sister chromatid exchanges, micronuclei and chromosomal aberrations and deletions [20], which have been found in peripheral lymphocytes of human exposed to formaldehyde [21]. However, this seems to occur only the site of the exposure, while also the evidence for the distant sites is not sufficient. In addition, it had been proven that formaldehyde can be systematically distributed after a pulpotomy procedure and animal studies have shown the systematically absorption of this substance in rats and dogs [20], but also another animal studies from [22], showed the relation between formaldehyde and development of squamous cell carcinoma in rats. In 2004, the International Agency for Research of Cancer classified formaldehyde as a carcinogenic in human beings, when there was sufficient evidence that it can cause nasopharyngeal cancer and strongly proof that it can provoke leukemia in humans, although the evidence about the relation between nasal/paranasal sinus carcinoma and formaldehyde is still limited [23]. On the other hand, dental studies led to different conclusions, and they support that the use of formocresol in pulpotomy is not mutagenic based on the result that chromosomal aberrations were found only in 5% of the patients after pulpotomy with this medicament [18]. According to [24] and [25], formaldehyde cannot also lead to genotoxicity and [19] showed that formocresol is not mutagenic maybe because the dose in case of a use as a pulpotomy material is not enough to provoke DNA damage.

B. Glutaraldehyde

Glutaraldehyde was introduced as a pulpotomy medicament from Gravenmade who suggested that this dialdehyde had better fixative properties and it can less diffuse the periapical tissues than the gold standard-formocresol. After the use of glutaraldehyde a homogenous eosinophilic zone is produced so the remaining pulp can keep its vitality [26]. According to [27] the success rate of glutaraldehyde is 82% at 25-months follow-up and worth mentioning is that based on other clinical studies the most common radiographic signs of failure of a pulpotomy treatment with glutaraldehyde are periodontal ligament widening (PDL), internal root resorption, furcation, and periapical radiolucency [28]. Also, clinical parameters play a significant role with pain, mobility and sinus formation the most common symptoms [28]. Reference [29] have also evaluated four different concentrations and types of glutaraldehyde and the results of the clinical study showed that there was no significant difference in the success rates between them. In addition, the main concern about glutaraldehyde is its relation to toxicity and mutagenicity which have been proved to be similar to formocresol [26] and combined with the lower success rates in comparison with formocresol, it is now longer considered as a material of choice for pulpotomy procedures [12].

C. Calcium Hydroxide

Calcium hydroxide (CH) is a crystal or white inorganic compound and regarding its mechanism of action it can lead to necrosis of the tissue surface, which can then passively calcify [30], is characterized from its high pH alkalinity [31] and its property to create a layer of hard tissue at the orifice which can promote pulp healing [32]. It is biocompatible with the ability to stimulate dentin formation and it also shows good antimicrobial properties. It has been proved that CH is efficient against microbes such as A. viscosus and L. acidophilus due to its high alkaline pH and the fact that these microbes can live in environment with lower pH [7]. According to studies, its success rates as pulpotomy material are significant lower that other used medicaments with only 64% success after 12 months follow-up [33]. Also, [34]

DOI: http://dx.doi.org/10.24018/ejdent.2022.3.1.138
compared the efficacy of mineral trioxide aggregate (MTA) and CH when they performed pulpotomy in 34 primary molars in total and they revealed that the success rate of the CH group was 64.7% with internal root resorption the most frequent sign of failure. Reference [35] presented also in their clinical trial in 139 pulpotomised primary molars in total that the CH group had at 24 months follow up 77% and 45% clinical and radiographic success rates respectively, which were significantly lower than the rates of the other two MTA groups of the same trial. Reference [14] showed that the total success rate after 12 months is 86% but at the 24months follow-up this rate dropped to 53%. Reference [32] also found that CH is related to clinical and radiographical signs such as pain, swelling, widening of the periodontal ligament and root resorption. Another clinical study also presented that internal and external root resorption is more frequent when CH was used as a pulpotomy material [14] and its cause may be the possible tunnels in the dentine bridge which can be the cause also for pulp irritation and finally the loss of the tooth [36] and that is the cause for the strong limitation of its use nowadays. However, calcium-enriched mixture cement has recently introduced which seems to lead to promising results. It can promote the dentinal bridge formation and by this way to help the remaining pulp tissue to maintain its vitality [37].

D. Ferric Sulfate

Ferric sulfate (FS) is a non-aldehyde coagulative agent [38], which was at first used as a pulpotomy material due to its haemostatic properties [39]. The mechanism of its action has been researched and it has been shown that it can form a barrier from a ferric-ion protein clot when it comes in contact with blood at the surface of the pulp and by this way the pulp tissue can maintain its vitality [40]. Clinical studies showed that FS is as successful as a pulpotomy agent as FC. The success rate after 20 months is 97.2% as the failure rate was 2.8% due to radiographic signs of internal root resorption without any clinical symptoms [41]. Almost the same promising results were presented also in other studies, where the radiographic success rate of FS was 96.7% without any clinical failure and the difference from other materials such as MTA was insignificant [42]. In addition, in another study which compared FS to two non-pharmaceutical pulpotomy techniques, it was presented that at the 9months follow-up the clinical success of FS was 86.6%, whereas the radiographic success rate was 80% with the internal resorption as the most frequent failure sign [43]. Furthermore, [44] compared FS to Biodentine and MTA and the results of the clinical trial showed that the success rate of FS at 12 months follow up was 82.75% and the difference between the above materials was statistically insignificant. Reference [45] performed in a total of 30 primary molars pulpotomy with FS, electrosurgery and laser in order to compare these three techniques and the results showed that at 12 months follow up the FS group had 80% clinical and radiographic success rate. Reference [46] also performed pulpotomy in 81 primary molars with FS, sodium hypochlorite and formocresol and they performed clinical and radiographic evaluation every month in a follow up period of 18 months. The results showed that at the last follow up FS had 87% clinical and 95.7% radiographic success rate and the difference was insignificant in comparison with the old gold standard. Also, according to [47] the clinical success rate of FS as a pulpotomy agent in 15 primary molars at 24 months follow up was 100% and the overall radiographic success rate was 87%. Another clinical trial from [48] also showed that FS led to great results with 100% radiographic success rate at 12 months follow up without any clinical symptoms, although this rate dropped to 85.7% 18 months after the pulpotomy. Reference [49] selected 71 primary molars with deep carious lesions, they performed pulpotomy with FS and they found that the overall success rate at 24 months follow up was 91.5%. Reference [50] divided 102 primary molars in two groups and they performed in the group of 79 teeth pulpotomy with FS and the results showed that the clinical and radiographic success rates of this group were 84% and 70% respectively. Also, worth mentioning is the pulpal response to the use of the FS as a pulpotomy agent from a histological sight. Regarding the production of reparative dentine, a dental bridge is present in almost all cases which covers or trying to bridge the site of the pulp exposure. FS can provoke also moderate inflammation of the pulp tissue and mild infiltration of macrophages and giant cells which was related to possibillity of healing of the remaining pulp [40]. According to the results above, FS is suitable as a pulpotomy agent, and it can lead to comparable results to the old standard-formocresol.

E. Mineral Trioxide Aggregate

Mineral trioxide aggregate (MTA) was introduced early 1990s and it was approved for human usage from FDA in 1998 [36]. It consists of a fine hydrophilic powder [48], it has an initial alkaline pH of 10.2 which during its settings reaches a pH of 12.5 and its main substances are calcium phosphate and calcium oxide [7]. It is a very bio compatible and bioactive material with good sealing abilities, and it also presents the property to promote regeneration when it comes in contact with the pulp tissue [36]. The mechanism of its action has been researched and it is now known that it is related to the hydration reaction and although MTA does not contain CH, it produces a calcium silicate hydrate with dissociates in CH molecules and the result is CH with a silicate matrix. Regarding its antimicrobial activity it has been presented that it is less efficient against S. mutans and A. viscosus comparing to other material such as CH and FS [7]. However, the sealing ability of MTA is considered as the one of its main advantages and based on a study which researched the microleakage of MTA in pulpotomies in primary molars, MTA presents significant less microleakage than other used materials with the condition that MTA is used in a dry environment [51]. From a histological sight, MTA results to the formation of the homogenous crystalline structure in the surface of its use and it can lead to a dentine bridge formation which works as a protective barrier for the remaining pulp tissue. It has been found that comparing to CH this dentine bridge is thicker and it is also extremely important that the pulp tissue responses to the use of MTA with less inflammation, less hyperemia and the necrosis is also very limited [36]. However, MTA has some disadvantages and limitations such as its high cost, difficult in manipulation, tooth discoloration and long setting time [52].

MTA is a material which has been researched a lot the last years and it has shown very positive results in cases of
pulpotomy in primary molars comparable to the formocresol. In a clinical study which compared FS and MTA as pulpotomy agents it was presented that at the 12 months follow-up the radiographic success rate of MTA was 96% without any clinical signs of failure [53]. Reference [13] also confirmed the superior success rates of MTA and their study resulted to 100% overall success rate after 12 and 18 months. According to another clinical study, pulpotomy in primary molars with MTA had 95% success rate at 12- and 24-months follow-ups with furcation radiolucency as the only radiographic sign [36]. Reference [54] presented in their clinical trial that the success rate of MTA group was 96% at 24 months follow up. Reference [55] also found that the radiographic success rate after 12 months is 96% and the only failure sign was internal resorption, which was then arrested with the replacement by calcified material. Reference [56] performed pulpotomy on 90 decayed primary molars with MTA and Biodentine and the outcomes of the clinical trial presented that at since the 9 months follow up the MTA group had 100% clinical and radiographic success rate and at the 12 months follow up the clinical success rate decreased to 95.5% and also only one tooth presented radiographic signs such as interradicular radiolucency and periodontal ligament widening. Additionally, according to [57] the MTA group in a clinical trial of 140 teeth in total presented the high clinical success rate of 100% at 24 months follow up and also 93.9% of the teeth treated with MTA had no radiographic signs of failure. Reference [58] divided primary molars in two group and they performed pulpotomy with MTA and Biodentine. They evaluated the pulpotomised teeth at 12,18, and 24 months follow ups and the results showed that the clinical success rate at the last follow up was 96.8% for both two medicaments while also the radiographic success rate of the MTA group was 87.1%. Reference [6] also observed in their clinical study the impressive results of MTA which had 92% success rate at 12 months follow-up with the internal resorption as the main radiographic sign. Furthermore, based on the clinical trial of [59] MTA showed 100% clinical and radiographic success rate 12 months after the pulpotomy procedure. Also, [42] performed pulpotomy with MTA in 27 primary teeth and the clinical and radiographic findings at 12 and at 24 months follow ups showed 100% success. Reference [60] also evaluated the effectiveness of MTA as pulpotomy agent and they found that at 24 months follow up the overall success rate of MTA group was 97.2%.

**F. Portland Cement**

The fact that MTA has been proved to be a material of choice for pulpotomy but with limitations as its high cost and the difficulty in its clinical use has led to the focus on the evolution of Portland Cement (PC). PC and MTA have many similarities in their structure as the PC is the main chemical component of MTA with the absence of bismuth ions and the presence of potassium ions in PC as the only differences between these two materials [61]. PC has also similar properties with MTA such as similar antibacterial activity and the ability to promote dentine bridge formation, but it is in some cases more preferable due to its lower-cost. However, PC has been related to a limitation regarding the radiopacity absence, which makes the addition of a radiopacifier necessary [61], [62]. Reference [62] researched through a clinical study the effectiveness of PC as a pulpotomy material and they also compared this medicament to MTA. The overall success rate was 100% after 12 and 24 months and there was no sign of pain, sinus, mobility or swelling and nonradiographic sign of failure such as internal resorption or/furcation radiolucency. Worth mentioning is also that dentine bridge formation was found in 2 of the 15 pulpotomised teeth at all follow-ups appointments. In addition, crown discoulouration was observed in all pulpotomised teeth, but this feature was slighter in teeth treated with PC. Also, [61] confirmed the promising results of this material as the success rate of PC was also 100% at 6-, 12-, and 24-months follow-ups. Reference [57] performed pulpotomy in 45 primary molars with PC, then the teeth were restored with stainless steel crows and the outcome of the trial was that this group had at 24 months follow up 93.9% and 86.7% clinical and radiographic success rate respectively. Furthermore, [63] confirmed the effectiveness of PC because the success rate at 12 months follow up was 100%, while also [64] found that PC led to completely successful results, and it is also very important that dentine bridge was present in some pulpotomised teeth. According to [65], histological description of PC has shown no inflammation and formation of dentin-like material which led to root canal obliteration.

**G. Biodentine**

Biodentine was firstly introduced in 2009 [66] and it is another calcium silicate cement with high alkaline pH [67]. Biodentine consists of a powder which is composed of tricalcium silicate, zirconium oxide and calcium carbonate and of a liquid which is mostly water, and it also contains water-soluble polymer and calcium chloride to obtain rapid setting time and high strength [13], [52]. It has the MTA-based cement technology and therefore it combines the advantages of MTA with some other better properties such as better and more convenient handling [66]. It is also a material which promotes dentine bridge formation and compared to calcium hydroxide has the ability to produce tighter seals [32]. Biodentine has presented good properties such efficient sealing ability, antimicrobial activity [66], quick setting time, biocompatibility, ability to promote hard tissue regeneration, stability, low solubility, and long-term impermeability [15].

Biodentine has been the last years researched and it has been compared to other pulpotomy medicaments with successful results. Reference [56] researched the effectiveness of Biodentine as pulpotomy agent and they showed through their clinical trial in 45 primary molars that this material had 95.5% clinical and radiographic success rate at 12 months follow up. Reference [15] demonstrated the outstanding results of Biodentine through their clinical trial in 112 primary molars and it was shown that at 12 months follow-up the overall success rate was 100%. Reference [32] confirmed the promising results of this medicament and they conducted a clinical trial in 400 primary molars in order to compare Biodentine and calcium hydroxide. They found that Biodentine led to better results as the clinical success rate was 96.5% and the radiographic one 90.1% after 18 months with resorption and periodontal ligament widening the most often signs of failure. Reference [13] came to the conclusion that Biodentine showed 93.3% radiographic success rate at 12 months follow-up but this rate dropped to 86.7% 18 months.
after the pulpotomy procedure due to internal resorption and furcation radiolucency. Reference [67] compared Biodentine and MTA and the results of this clinical study showed that the total success rate of Biodentine was 89.4% at 12, 18, and 24 months follow-ups which was a little lower that the rate of MTA but this difference was characterized as insignificant. Also, [68] compared Biodentine and formocresol and they presented that Biodentine had 97.3% success rate which was higher than the success rate of the old gold standard, while [66] also confirmed the high effectiveness of Biodentine as a pulpotomy medicament as the overall success rate of this material in their clinical trial was 94% at 9 months follow up. The study of [60] also presented that Biodentine led to great results as they revealed that this medicament had 97.4% overall success rate at the 24 months follow up.

H. Sodium Hypochlorite

Sodium Hypochlorite (SH) was used at first in the field of dentistry as an irrigant agent in root canal treatments in permanent teeth since 1920s [69]. Nowadays it is a material of choice for hemostasis, removal of debris and biofilm, irrigation of root canals and it is also used as a medicament for pulpotomy in primary teeth [17]. SH has very good antibacterial properties and Rosenfeld, [70] have shown that 5% NaOCL acts only superficially without being irrigant to the deeper pulp tissue. Reference [71] showed that after the use of 3% NaOCL, a normal soft tissue reorganization and dentinal bridge formation were observed in 86% of the treated pulps. Reference [72] came to the result that 3% NaOCL can be used as a medicament in pulpotomies and that this material is related to promising results and to normal pulps when the microleakage in the pulp-restoration surface is also limited. Reference [73] presented also that 5% NaOCL has showed successful results as a medicament for pulpotomies with 100% clinical and 79% radiographic success rate at 12 months follow-up. Reference Bawazir [74] presented in their clinical trial that the pulpotomised primary molars of the SH group had 94.6% and 86.5% clinical and radiographic success rate respectively. In addition, [69] based on 147 pulpotomised primary molars with NaOCL performed follow ups at 6, 12 and 24 months and they found that the clinical success rate was 97% 12 months after the pulpotomy procedure and that this rate remained the same until the last of the follow up period. Also, in the same research the radiographic success rate was 89% at the second follow up but this rate dropped to 77% at the last evaluation. Reference [75] revealed that the group of primary molars which were pulpotomised with NaOCL presented 100% and 85% clinical and radiographic success rates at 6 months follow up respectively. Furthermore, histologic studies also showed that SH is a suitable material for pulpotomies because compared to formocresol, SH leads less to severe inflammation of the pulp tissue, and it can also promote dentinal bridge formation maybe due to the maintenance of the pulp vitality [17].

I. Electrosurgery

Electrosurgery (ES) is an alternative, non-pharmacological pulpotomy technique which seems to have promising results, and which can lead to good visualisation and hemostasis [38]. The mechanism of its action has been researched and it is now known that the procedure of ES carbonizes and denatures the pulp tissue, and the result is the production of a layer of coagulative necrosis which protects the remaining pulp tissue beneath the lining base material [76]. Reference [77] compared the success rates between pulpotomy with electrosurgery and pulpotomy with the old gold-standard formocresol and this study showed that the clinical success rate of ES pulpotomy was 96% and the radiographic 84% with root resorption and internal root resorption the most common radiographic signs of failure, while formocresol led to better results but the difference between them was statistically insignificant. Reference [37] also confirmed the successful results of ES as their clinical trial showed that the radiographic success rate at 12 months follow-up was 98% without any clinical symptoms. Reference [43] divided 45 primary molars equally in three groups and the clinical and radiographic success rates of the ES group at 9 months follow up were 100% and 80% respectively with internal resorption the most frequent sign of failure. Also, [45] found that ES led in their clinical trial to 80% clinical and radiographic success rate in a group of ten pulpotomised primary molars at 12 months follow up.

J. Laser

Laser is a nonconventional, non-pharmacological technique, which has been recommended the last decades in different endodontic treatments including pulpotomy [78]. Laser is considered to present important advantages such as the potential to promote healing, to stimulate dentinogenesis and to preserve the vitality of the remaining pulp tissue [66]. Laser treatment can also provide control of hemorrhage, sterilization and the possibility to remove the soft tissue without causing trauma to the residual tissues [79]. The need to find new materials and techniques which can be used in pulpotomy procedure with efficient results and the promising advantages of laser led the last years to the investigation of several laser types such as diode, carbon dioxide, argon, Er:Yag and Nd:Yag. laser.

Diode laser is considered to be suitable for pulpotomy treatment because of its high absorbance at the wavelength at which energy is produced in dental pulp tissue and its potential to leave the other tissues unaffected. Studies have also shown that laser pulpotomy compared to formocresol-ZOE pulpotomy has a reduced radiographic success rate, which was statistically insignificant while also all patients were free of symptoms and clinical signs of failure [80]. Reference [45] showed that the diode laser group in their clinical trial presented 100% overall success rate and that this pulpotomy technique was the most successful compared to the groups of electrosurgery and ferric sulfate of their study. In addition, [81] evaluated the success rate of a carbon dioxide laser pulpotomy and they found that this treatment option presented comparable results which a conventional pulpotomy with formocresol. Er:Yag laser is also an alternative as it is hemostatic, antimicrobial and because it has cell-stimulating properties. Reference [14] compared the results of Er:Yag laser pulpotomy with other three more conventional techniques and they found that the overall success rate of laser therapy was 93% and 78% at the 12 months and the 24 months follow-up respectively, which difference was insignificant with the success rate of the old gold standard formocresol. In another study, which evaluated the pulpotomy using Er:Yag laser, Biodentine and MTA,
results showed that the success rate of pulpotomy with laser was 78.5% after 9 months which was lower compared to other two groups but the researchers concluded that Er:Yag laser can effectively be used in pulpotomy procedure [66]. Furthermore, [82] investigated the bacterical effect of Nd:Yag laser and they achieved to eliminated the bacteria in the root canals to 99.9%. Also, in a study of [79] 42 teeth were pulpotomised in order to compare the results of pulpotomy with Nd:Yag laser and formocresol and the clinical trial showed that the clinical success rate of Nd:Yag laser pulpotomy was 85.71% at the 12 months follow-up and the radiographic success rate was 71.42% and the difference between the two groups was considered statistically insignificant.

K. Zinc Oxide Eugenol

Zinc oxide eugenol (ZOE) has been used many years as a coronal dressing material after the use of a pulpotomy agent for the amputation of the dental pulp. ZOE is an antibacterial material with low cost, which is easy to handle during clinical procedures [83] but due to eugenol was not recommended for direct contact with the pulp tissue [84]. However, there are a few studies which have researched the effectiveness of ZOE as pulpotomy material. Reference [85] found that the sterile compression of ZOE or ferric sulfate in 145 primary molars led in both groups to 100% success rate after 3 months. Also, [86] performed pulpotomy in 190 primary molars with reinforced ZOE as the only pulpotomy agent and the clinical and radiographic success rates were 97% and 95% respectively. Reference [87] also evaluated ZOE as pulpotomy medicaments and for this reason they performed pulpotomy in 60 decayed primary molars and the outcomes of the trial showed that at 24 months follow up 51/60 pulpotomised teeth had not clinical or radiographic signs of failure. The other 9 teeth presented clinical symptoms and regarding the radiographic signs the most frequent were furcal and periapical radiolucency and root resorption. According to [54], the success rate of ZOE as the only pulpotomy medicament was 68% at 24 months follow up, which was significantly lower than the MTA group in the same clinical trial.

L. Calcium Enriched Mixture Cement

Calcium enriched mixture cement (CEM) is a calcium silicate-based cement, which was firstly used in dentistry in 2006. It consists of a liquid and a powder, which mostly contains calcium oxide, sulfur trioxide, phosphorous pentoxide, and silicon dioxide. It has specific features with great significance such as high biocompatibility, antimicrobial activity, and primary setting time, but also worth mentioning is its ability to promote dentine bridge formation [88], [89]. Reference [37] compared the success rates of CEM and electrourgery through a clinical trial on 102 primary molars and they presented that CEM led to 90% radiographic success without any clinical signs of failure at 24 months follow-up.

M. Calcium Phosphate Cement

Calcium phosphate cement (CPC) is a hydraulic cement which has been researched as a pulpotomy medicament. Reference [90] came to the conclusion that this material maybe belongs to the future pulpotomy medicaments. Furthermore, [91] also evaluated the suitability of CPC and therefore they performed pulpotomy on canines and the histological examination showed that CPC led to less inflammation of the remaining dental pulp in comparison to formocresol and also that CPC promoted the dental bridge formation.

N. Lyophilized Platelet-Derived Preparation

Lyophilized platelet-derived preparation (LPDP) has also focused the interest as a potential pulpotomy agent and based on the clinical trial of [92], it was used as a pulpotomy medicament on 28 teeth, which were evaluated at 1, 3 and 6 months follow ups, and it was proved that it led to better results in comparison with the other group of teeth which were pulpotomised with calcium hydroxide. Additionally, [93] performed pulpotomy on 40 primary molars with platelet-rich fibrin and LPDP in order to compare these two pulpotomy agents and the results showed that LPDP had 95% success rate at 6 months follow up, which was better outcome than the success rate of the other group.

O. Platelet-Rich Fibrin

Platelet-rich fibrin (PRF) has also been researched as a material for pulpotomy in primary teeth. It is an autologous material, which is according to [93] a promising medicament for pulpotomy as they found in this clinical trial that this material can achieve 90% success rate at the 6 months follow-up. Also, [94] evaluated the effectiveness of PRF and they compared it to MTA through a clinical trial on 50 primary molars and the results of the study showed that the overall success rate was 90% 6 months after the pulpotomy procedure.

P. Recombinant human platelet-derived growth factor

Recombinant human platelet-derived growth factor (rhPDGF) presents the ability to promote dentinogenesis but the mechanism of its action has not since today totally understood. Reference [95] and [96] researched the rhPDGF in combination with MTA and with Ca(OH)2 in two different clinical trials and they confirmed the presence of a hard tissue formation of a dentine-like structure with normal features such as porosity and efficient thickness in the rhPDGF+MTA group and worth mentioning is that this structure presented similar features with the secondary dentin. Also, in the other study they found that in the rhPDGF+Ca(OH)2 a hard tissue formation was also present but with the difference that in this group this structure was not consistent and it had also differences in comparison to the secondary dentin.

Q. Bioactive Glass

Bioactive glass belongs to the class of osteoconductive biomaterials, which presents the property to produce a superficial layer of hydroxycarbonate apatite [97], [98]. Reference [97] researched the bioactive glass as potential pulpotomy medicament through an in vivo study on rat molars and the histological evaluation showed at 2 weeks the presence of pulpal inflammation which was severe enough to provoke internal resorption in a sample and periapical abscess formation in another sample. Although, at 4 weeks evaluation the initial inflammation seemed to be limited. In addition, [99] showed that bioactive glass led to 100% clinical and 84% radiographic success rate 12 months after the pulpotomy.
procedure. Although, [100] in order to compare the 70S30C bioactive glass to Biodentine, they pulpotomised primary teeth and they performed follow ups until 12 months after the pulpotomy procedure. The results showed that at 3 months follow up all teeth in the group of bioactive glass presented clinical signs of failure due to persisting inflammation.

R. Hydroxyapatite Crystals

Hydroxyapatite is the main component of the inorganic part of the hard tissue of the teeth, and it has been also the last years researched as a pulpotomy agent. Reference [101] performed pulpotomy on primary molars with hydroxyapatite and the results of this clinical trial showed 80.33% radiographic success rate without clinical symptoms at 6 months follow up. Reference [102] performed pulpotomy on pig teeth and the histological evaluation showed absence of severe inflammation and also the researchers came to the conclusion that hydroxyapatite can be a suitable material for pulpotomy. Furthermore, [99] found in their clinical trial on pulpotomised primary molars that the pulpotomy with hydroxyapatite crystals showed 100% clinical and 84% radiographic success rate at 12 months follow up.

S. Freeze-Dried Bone

Freeze-dried bone was evaluated from [103] as a pulpotomy agent and they performed pulpotomy on primary and permanent teeth of monkeys. The histological evaluation showed that the pulpotomised teeth maintained the vitality of the apical part of the remaining pulp tissue and also worth mentioning is the presence of a calcific barrier in all but three teeth.

T. Bone Morphogenetic Proteins

Bone morphogenetic proteins (BMPs) is a family of proteins, which have bone-inductive properties and they are implicated in cell differentiation, tissue morphogenesis, regeneration, and repair. Studies based on animals have shown that BMP has the potential to stimulate the induction and differentiation of mesenchymal cells with varying degrees of dentine bridge formation [12]. Other studies have also presented that BMP-7 may be able to mediate epithelial-mesenchymal interactions during the initiation phase of odontogenesis and morphogenesis [104]. Although, in a study on pulpotomised animals’ teeth, BMP-7 and BMP-2 were not able to induce dentine formation [105].

U. Enamel Matrix Derivative

Enamel matrix derivative (EMD) is a protein extract from unerupted porcine tooth buds, which contains 90% amelogenins and smaller amounts of tuftelin, ameloblastin, enamelin and other nonamelogenin proteins and it is used for the treatment of periodontal defects and soft tissue recession [106]. Reference [107] showed with their study on pigs’ teeth that EMD can lead to better results than Ca(OH)₂ because it can promote dentine bridge formation without affecting the remaining pulp tissue. Although, another study on dogs from [108] presented that EMD led earlier than Ca(OH)₂ to the formation of dentine bridge but the EMD group presented after three months pulpal inflammation and disintegration of the pulp.

V. Collagen

Cross-linked collagen gel and enriched collagen solution have been reported as pulpotomy medicaments in animals. Studies have shown different responses including complete regeneration of the pulp tissue and dentine bridge formation, but it is worth to mention that these studies were carried out only on non-inflamed pulps [12]. Reference [109] demonstrated that a commercial collagen preparation with the name Zyderm (Colagen Corp. Palo Alto, CA) led to unacceptable results because only 4% presented dentine bridge formation and the collagen group was also related to total or partial necrosis and severe inflammation. However, an in vivo study, which compared collagen-based pulpotomy and conventional pulpotomy with formocresol, showed very promising results as the collagen group led overall to higher success rate [110].

III. DISCUSSION-CONCLUSION

Pulpotomy is a type of vital pulp treatment, which can lead to high success rates, when it is selected as a treatment of choice with strict criteria. The right diagnosis, the right selection of patients who present reversible pulp inflammation due to caries or trauma, the performance of the pulpotomy technique with proper isolation and with the suitable technique and medicament and also a final restoration, which is against microleakage are among the most important key factors for the success of the pulpotomy. Reference [111] researched the prognostic factors for the success of the pulpotomy with MTA and the outcomes of the study showed that important role also plays the type of the arch and the tooth as it was proved that mandibular deciduous molars were related to higher failure rate. Furthermore, pulpotomy on primary molars with caries below the cementoenamel junction had worse results in comparison with the pulpotomised molars with less extended caries and significant was the type of the final restoration as the stainless-steel crowns were proved to be the most reliable and proper choice.

The selection of the right pulpotomy medicament is also considered to be crucial in order a pulpotomised primary tooth to maintain its vitality and to maintain also in the arch until its normal exfoliation. The ideal pulpotomy material has to be biocompatible, antibacterial, harmless to the surrounding tissues, no irritating to the pulp tissue and it is also important that this material can promote the healing of the remaining pulp and not interfere the normal root resorption of the deciduous teeth. Nowadays there is a variety of medicaments, which can be used for the procedure of pulpotomy in primary teeth. Formocresol was the old gold standard because of the many clinical trials which proved the high success rates of this medicament but the last years its use has been limited due to serious concerns about its safety. Moreover, glutaraldehyde is not considered as a suitable pulpotomy medicament not only for safety reasons but also because it led to worse success rates compared to other medicaments. Also, it has been proved that calcium hydroxide leads to lower clinical and radiographic success rates with the root resorption the most frequent cause of failure and it is no longer recommended as a pulp dressing.
material. However today, materials as ferric sulfate, MTA, Biodentine and Portland cement are among the most favorable pulpotomy agents with very important advantages and great effectiveness. Ferric sulfate proved to be a safe material with clinical results comparable to the old gold standard and the fact that ferric sulfate has less setting time, makes it easier to handle during the clinical procedure of pulpotomy. Based on the results of the clinical studies which are included in this review, the success rate of ferric sulfate is between 80-97.2% with the only exception of one study which resulted in 70% success rate of this medicament. Also, MTA has led to great outcomes and a high effectiveness between 87.1%-100% and therefore it is considered to be a material of choice, but it has some limitations such as its high price and its difficulty in manipulation. Furthermore, the discoloration is another very important disadvantage of MTA because it limits the use of this material on anterior teeth for aesthetic reasons. Biodentine and Portland cement seem to be also suitable choices with high overall success rates. Furthermore, electrosurgery is an alternative non-pharmacological technique with success rate not lower than 80% according to the above clinical trials. Laser is another non-conventional technique for pulpotomy, which have led according to studies also to positive results depending also on the type of the selected laser. Sodium hypochlorite has shown the last years that it is a promising medicament with antibacterial properties and the significant property to maintain the vitality of the remaining pulp tissue, while also its effectiveness is based on the literature not lower than 77%-24 months after the pulpotomy procedure. Zinc oxide eugenol was researched in a few studies as pulpotomy medicament, and the results were quite controversial because of the significant difference between the success rates of this material in the above clinical trials. Also, many medicaments including calcium enriched cement, calcium phosphate cement, bioactive glass and hydroxyapatite crystals have been more researched the last years and the studies showed promising results and that these materials can be potential alternatives for pulpotomy, but more research is needed. Regarding the platelet rich fibrin and the lyophilized platelet-derived preparation were evaluated and compared to other more conventional pulpotomy agents in a few research and the success rates seem to be also high, whereas recombinant human platelet-derived growth factor showed to have the ability to promote dentine-bridge formation. Additionally, freeze-dried bone, bone morphogenetic proteins, enamel matrix derivative and collagen have been researched but since today there are almost only studies on animals.

CONFLICT OF INTEREST

Authors declare that they do not have any conflict of interest.

REFERENCES

[1] Who.int. Oral Health [Internet]. 2020 [updated 2020 March 25]. Available from: https://www.who.int/news-room/factsheets/detail/oral-health

[2] Frencken JE, Sharma P, Stenhous L, Green D, Laverty D, Dietrich T. Global epidemiology of dental caries and severe periodontitis - a comprehensive review. J Clin Periodontol. 2017; 44(18): 94-110.

[3] Bjornsdal L, Simon S, Tomson PL, Duncan HF. Management of deep caries and the exposed pulp. Int Endod J. 2019; 52(7): 949-973.

[4] American Academy of Pediatric Dentistry. Pulp therapy for primary and immature permanent teeth. The Reference Manual of Pediatric Dentistry. Chicago, Ill.: American Academy of Pediatric Dentistry; 2020:384-92.

[5] Fuks AB. Vital pulp therapy with new materials for primary teeth: new directions and Treatment perspectives. Pediatr Dent. 2008; 30(3): 211-9.

[6] Rajasekharan S, Martens LC, Vandenbuckele J, Jacquet W, Bottenberg P, Caussels RG. Efficacy of three different pulpotomy agents in primary molars: a randomized control trial. Int Endod J. 2017; 50(3): 215-228.

[7] Pimenta HC, Borges AH, Bandeira MC, Neves AT, Fontes RG, da Silva PV, et al. Antimicrobial activity of filling materials used in primary teeth pulpoty. J Int Oral Health. 2015; 7(4): 54-57.

[8] Pinkham JR, Casamassimo PS, McGinty DJ, Fields HW & Nowak AJ. Pulp therapy for the primary dentition. Pediatric dentistry: Infancy through adolescence. 4th edition. St.Louis, Missouri. Elsevier Saunders, 2005; 22: 375-393.

[9] Buckley JP. The chemistry of pulp decomposition with a rational treatment for this condition and its sequelae. American Dental Journal 1904; 3: 764–771.

[10] Sweet CA, Jr. Procedure for treatment of exposed and pulpless deciduous teeth. Journal of the American Dental Association. 1930; 17: 1150–1153.

[11] Chakraborty A, Dey B, Jana S. A Nonconventional approach to formocresol pulpoty. Int J Clin Pediatr Dent. 2018; 11(6): 490-495.

[12] Srinivasan V, Patchett CL, Waterhouse PJ. Is there life after Buckley's Formocresol? Part I -- a narrative review of alternative interventions and materials. Int J Paediatr Dent. 2006; 16(2): 117-27.

[13] Jungra J, Kalkami S. Clinical and radiographic comparison of biodentine, mineral trioxide aggregate and formocresol as pulpotomy agents in primary molars. Eur Arch Paediatr Dent. 2017; 18(4): 271-278.

[14] Huth KC, Paschos E, Hajek-Al-Khatar N, Holloweck R, Crispin A, Hickel R, et al. Effectiveness of 4 pulpotomy techniques--randomized controlled trial. J Dent Res. 2005; 84(12): 1144-8.

[15] El Meligy OAES, Alamoudi NM, Alazzam SM, El-Housseiny AAM. Biodentine TM versus formocresol pulpotomy technique in primary molars: a 12-month randomized controlled clinical trial. BMC Oral Health. 2019; 19(1): 3.

[16] Ruby JD, Cox CF, Mitchell SC, Makhsit S, Chompu-Insawi P, Jackson J. A randomized study of sodium hypochlorite versus formocresol pulpotomy in primary molar teeth. Int J Paediatr Dent. 2013; 23(2): 145-52.

[17] Haghgoo R, Abbasi F. A histopathological comparison of pulpotomy with sodium hypochlorite and formocresol. Iran Endod J. 2012 Spring; 7(2): 60-2.

[18] Lewis BB, Chestner SB. Formaldehyde in dentistry: a review of mutagenic and carcinogenic potential. J Am Dent Assoc. 1981; 103(3): 429-34.

[19] Zaeer PA, Rosenblatt A, Takahasi CS, Takeuchi PL, Costa Júnior LA. Formocresol mutagenicity following primary tooth pulp therapy: an in vivo study. J Dent. 2003; 31(7): 479-85.

[20] Milnes AR. Is formocresol obsolete? A fresh look at the evidence concerning safety issues. J Endod. 2008; 34(7): 40-6.

[21] Casas MJ, Kenny DJ, Judd PL, Johnston DH. Do we still need formocresol in pediatric dentistry? J Can Dent Assoc. 2005; 71(10): 749-51.

[22] Swenberg JA, Kerns WD, Mitchell RI, Gralla EJ, Pavkov KL. Induction of squamous cell carcinomas of the rat naso cavity by inhalation exposure to formaldehyde vapour. Cancer Research. 1980; 40: 3398-3402.

[23] Patchett CL, Srinivasan V, Waterhouse PJ. Is there life after Buckley's formocresol? Part II - Development of a protocol for the management of extensive caries in the primary molar. Int J Paediatr Dent. 2006; 16(3): 199-206.

[24] Ribeiro DA, Marques ME, Salvadori DM. Lack of genotoxicity of formocresol,paramonochlorophenol and sodium hydioxide on mammalian cells by comet assay. J Endod. 2004; 30: 593-6.

[25] Ribeiro DA, Scluncti C, De Lima PL, Marques ME, Salvadori DM. Genotoxicity of antimicrobial endodontic compounds by single cell gel (comet) assay in Chinese hamster ovary (CHO) cells. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005; 99: 637–40.

[26] Waterhouse PJ. Formocresol and alternative primary molar pulpotomy medicaments: a review. Endod Dent Traumatol. 1995; 11: 157-162.

[27] Fuks AB, Bimstein E, Keln H. Assessment of a 2 percent buffered glutaraldehyde solution in pulpotomized primary teeth of school
Al-Hezaimi K, Naghshtbandi J, Alhuzaeei R, Alonaizan F, AlQiwizani I, Rotstein I. Evaluation of recombinant human platelet-derived growth factor or enamel matrix derivation plus calcium hydroxide for pulp capping: a randomized controlled human clinical trial. Int J Periodontics Restorative Dent. 2020; 40(5): 645-654.

Salako N, Joseph B, Ritwik P, Salonen J, John P, Jannia T. Comparison of bioactive glass, mineral trioxide aggregate, ferric sulfate, and formocresol as pulpotomy agents in rat molar. Dent Traumatol. 2003; 19(6): 314-20.

Jones JR, Ehrenfried LM, Henc LH. Optimizing bioactive glass scaffolds for bone tissue engineering. Biomaterials. 2006; 27: 964-973.

Neeraja Govindaraj, Kinjal Shah Virani, Priya Subramaniam, Megha Gupta. Evaluation of bioactive glass and glassyapatite crystals as pulpotomy agents in primary molars: A clinical study. Contemp Pediatr Dent. 2020; 1(1): 42-51.

Elhamouly Y, El Backly RM, Talaat DM, Omran SS, El Tantawi M, Dowidar KML. Tailored 70S30C Bioactive glass induces severe inflammation as pulpotomy agent in primary teeth: an interim analysis of a randomised controlled trial. Clin Oral Investig. 2021; 25(6): 3775-3787.

Adlakha VK, Chandra P, Joshi J, Thomas A, Singh N. A comparative evaluation of hydroxyapatite crystals and glutaraldehyde as agents for pulpotomy in deciduous molars. Int J Clin Pediatr Dent. 2009; 2(1): 13-22.

Shayegan A, Atash R, Petriein M, Abbeeve AV. Nanohydroxyapatite used as a pulpotomy and direct pulp capping agent in primary pig teeth. J Dent Child (Chic). 2010; 77(2): 77-83.

Fadavi S, Anderson AW, Punwani IC. Freeze-dried bone in pulpotomy procedures in monkeys. J Pedod. 1989; 13(2): 108-22.

Wang YH, Rutherford B, Upholt WB, Mina M. Effects of BMP-7 on mouse tooth mesenchyme and chick mandibular mesenchyme. Dev Dyn. 1999; 216: 320-335.

da Silva LA, de Paula e Silva FW, Leonardo MR, Assed S. Pulpal and periapical response of dogs' teeth after pulpotomy and use of recombinant human bone morphogenetic protein-7 as a capping agent. J Dent Child (Chic). 2007; 74(2): 79-84.

Wang HH, Sarmast ND, Shadmehe E, Angelov N, Shabahang S, Torabinejad M. Application of enamel matrix derivative (Enmodag) in endodontic therapy: A comprehensive literature review. J Endod. 2018; 44(7): 1066-1079.

Nakamura Y, Hammarström L, Matsumoto K, Lyngstad S. The induction of reparative dentine by enamel proteins. Int Endod J. 2002; 35(5): 407-17.

Darwish SS, Abd El Meguid SH, Wahba NA, Mohamed AA, Chrzanowski W, Abou Neel EA. Root maturation and dentin-pulp response to enamel matrix derivative in pulpotted in permanent teeth. J Tissue Eng. 2014; 5: 2041731415421707.

Fuks AB, Jones PC, Michaela Y, Bimstein E. Pulp response to collagen and glutaraldehyde in pulpotted primary teeth of baobos. Pediatr Dent. 1991; 13(3): 142-50.

Anandan V, Inbanathan J, Saket P, Krishnamoorthy V, Gandhi S, Chandrababu VK. Assessment of clinical and radiographic success rate of formocresol-based pulpotomy versus collagen-based pulpotomy: An in vivo Study. J Contemp Dent Pract. 2021; 22(6): 680-685.

Kim CH, Bae JS, Kim HH, Song JS, Choi HJ, Kang CM. Prognostic factors for the survival of primary molars following pulpotomy with mineral trioxide aggregate: A retrospective cohort study. Clin Oral Investig. 2021; 25(4): 1797-1804.